Update!
$Actinium (ATNM.US)$ Actinium Announces NIH Grant Extension to Advance Clinical Development of Next-Generation CD45 Targeted Conditioning Agent Iomab-ACT with Memorial Sloan Kettering's CAR-T Cell Therapy
Disclaimer: Community is offered by Moomoo Technologies Inc. and is for educational purposes only.
Read more
Comment
Sign in to post a comment
